Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial

Dimopoulos, ALİ; Terpos, Evangelos; Boccadoro, Mario; Delimpasi, Sosana; BEKSAÇ, MERAL; Katodritou, Eirini; Moreau, Philippe; Baldini, Luca; Symeonidis, Argiris; Bila, Jelena; Oriol, Albert; Mateos, Maria-Victoria; Einsele, Hermann; Orfanidis, Ioannis; Ahmadi, Tahamtan; Ukropec, Jon; Kampfenkel, Tobias; Schecter, Jordan; Qiu, Yanping; Amin, Himal; Vermeulen, Jessica; Carson, Robin; Sonneveld, Pieter

doi:10.1016/s1470-2045(21)00128-5

Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial

Copy For Citation

Dimopoulos M. A., Terpos E., Boccadoro M., Delimpasi S., BEKSAÇ M., Katodritou E., ...More

LANCET ONCOLOGY, vol.22, no.6, pp.801-812, 2021 (SCI-Expanded)

Publication Type: Article / Article
Volume: 22 Issue: 6
Publication Date: 2021
Doi Number: 10.1016/s1470-2045(21)00128-5
Journal Name: LANCET ONCOLOGY
Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, CAB Abstracts, CINAHL, EMBASE, MEDLINE
Page Numbers: pp.801-812
Erciyes University Affiliated: Yes

Abstract

Background In a phase lb study, intravenous daratumumab plus pomalidomide and dexamethasone induced a very good partial response or better rate of 42% and was well tolerated in patients with heavily pretreated multiple myeloma. We aimed to evaluate whether daratumumab plus pomalidomide and dexamethasone would improve progression-free survival versus pomalidomide and dexamethasone alone in patients with previously treated multiple myeloma.